Drugs / SKL15508
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT02205099 | Jul 2014 → Jun 2015 | schizophrenia | SK Life Science, Inc. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SKL15508 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02205099 ↗ |
| Route | Oral | “Multiple Oral Doses of SKL15508” NCT02205099 ↗ |